MFG
KNSA icon

Merit Financial Group’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Merit Financial Group’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$350K Buy
5,474
+59
+1% +$3.06K ﹤0.01% 1724
2026
Q1 		$261K Buy
+5,415
New +$240K ﹤0.01% 1749

Other funds holding KNSA

PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
LTAS
Linden Thomas Advisory Services Charlotte, North Carolina $1.24B AUM 47.37% 1-Year Est. Return
FEG
Financial Enhancement Group Anderson, Indiana $839M AUM 18.63% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
JWS
Juncture Wealth Strategies Scottsdale, Arizona $384M AUM 27.62% 1-Year Est. Return
AAM
AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return
PAS
Park Avenue Securities New York $16B AUM 26.77% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Merit Financial Group's KNSA Position: Q2 2026 in Review

Merit Financial Group increased its Kiniksa Pharmaceuticals (KNSA) stake by 1.1% in Q2 2026, buying an estimated $3.06K and bringing the position to 5,474 shares worth $350K. The position accounts for ﹤0.01% of the portfolio, ranked #1724.

Merit Financial Group first reported a position in KNSA in Q1 2026 and has held it in 2 quarters since. 25 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Merit Financial Group held 5,474 shares of Kiniksa Pharmaceuticals worth $350K as of Q2 2026.
  • Merit Financial Group bought 59 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $3.06K.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of Merit Financial Group's portfolio in Q2 2026, its #1724 holding.
  • Merit Financial Group first reported a position in Kiniksa Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 25 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Merit Financial Group's 13F filing for Q2 2026, filed 17 Jul 2026.